← Leaderboards
Hongyan Zhou
Acurastem, Inc.
$1,581,576
Attributed
$3,163,151
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2018–20$2M$1.5M$1M$500K$0
'18
'19
'20
Funding mix
By agency
NIH$3,163,151 · 1
By mechanism
R44$3,163,151 · 1
Top collaborators
- Samuel V Alworth4 shared
Most similar at Acurastem, Inc.
Same institution · by research overlap
- Samuel V Alworth$4,714,159
- Wen-Hsuan Chang$2,212,802
- Zhihua Feng$2,782,758
- Qing Liu-Michael$112,468
Others in their field
Other Emerging Leaders on “Accounting”
- Martha Hering · Westat, Inc.$57,098,843
- John Hobbs · Suny At Stony Brook$41,239,084
- Christopher Bee · Suny At Stony Brook$41,239,084
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
- Pamela Winer Goldberg · Medical Device Innovation Consortium$28,780,000
- Stephen F Kry · University Of Tx Md Anderson Can Ctr$28,689,457
Research focus
AccountingInhibitor/AntagonistAnalogAnimal Model3-DimensionalAmyotrophic Lateral SclerosisAutopsyBaseBiochemicalBlood - Brain Barrier AnatomyAntisense OligonucleotidesClinicCollectionAutophagocytosisDefectDisease ModelDrug DiscoveryEvaluationExhibitsFrontotemporal Lobar Dementia-Amyotrophic Lateral SclerosisGeneticHomology ModelingC9orf72In Vitro Assay
Grant awards (4)
PIKFYVE antagonism as a therapy for C9ORF72-ALS/FTD$1,148,751
R44 · FY2020 · NS
PIKFYVE antagonism as a therapy for C9ORF72-ALS/FTD$1,316,216
R44 · FY2019 · NS
PIKFYVE antagonism as a therapy for C9ORF72-ALS/FTD$265,079
R44 · FY2019 · NS
PIKFYVE antagonism as a therapy for C9ORF72-ALS/FTD$433,105
R44 · FY2018 · NS